TGFB1 and B-cell chronic lymphocytic leukemia: Specifically in CLL, the TGF-β pathway has been described as an axis that can contribute to the clinical and biological progression, albeit not in all patients [27,30], which underlines the importance of the different heterogeneity layers that exist in CLL.